Sleep

Latest News


CME Content


The FDA has approved Merck's Belsomra (suvorexant), a Schedule IV substance, for the treatment of insomnia, as characterized by difficulties with sleep onset and/or sleep maintenance.

John W. Devlin, PharmD, FCCM, FCCP, a clinical pharmacist in the medical ICU at Tufts Medical Center, discusses sleep's role in treating patients in the ICU.

People who have sleep apnea or spend less time in deep sleep may be more likely to have changes in the brain that are associated with dementia.